Study Overview: This study is testing a new treatment called CB-012 for adults with a type of blood cancer called acute myeloid leukemia (AML). AML is a cancer of the blood and bone marrow where the body makes abnormal blood cells. The treatment uses special cells called CAR-T cells, which are modified immune cells designed to attack cancer cells. The study is for patients whose AML has come back or doesn't respond to other treatments.

Eligibility: To join, you must have AML that is either relapsed or refractory, have tried 1 to 3 other treatments, and be healthy enough for stem cell transplant. You cannot join if you have certain other health conditions or have had previous CAR-T cell therapy.

Key Points to Consider:

• The study is in Phase 1, focusing on safety and how the body reacts to the treatment.
• Participants must agree to use effective birth control if they could have children.
• Prior CAR-T therapy or recent stem cell transplant disqualifies participation.

Consider discussing with your doctor if this study might be right for you.